Table 1

Key funding mechanisms for global health R&D, launched 2013–2016

Funding mechanismLaunch yearPartnersDescriptionFunding mobilised (by 2018)
Global Health Investment Fund (GHIF)2013Bill & Melinda Gates Foundation, J.P. MorganMobilises capital from high-net worth individuals and institutions to fund late-stage innovations for neglected diseases, seeking social impact and a return on investmentUS$108 million
Global Health Innovative Technology Fund (GHIT Fund)2013Japanese government, Japanese pharmaceutical companies, Bill & Melinda Gates Foundation, Wellcome Trust, United Nations Development ProgrammeInvests in the discovery, preclinical, and other development phases of neglected disease projects, including HIV/AIDS, malaria, TB and NTDsUS$345 million committed
(US$145 million in funding from 2013 to 2017 and US$200 million secured for 2018–2020)
Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X)2016Wellcome Trust, US Department of Health and Human Services Biomedical Advanced Research and Development Authority, US National Institute of Allergy and Infectious Disease, UK Department of Health and Social Care, Bill & Melinda Gates Foundation, Boston UniversityProvides grants, scientific and business support to advance the early stages of innovative antibiotics and other therapeutics, vaccines, rapid diagnostics and devices to address drug-resistant bacterial infections$500 million from 2016 to 2021
Global Antibiotic Research and Development Partnership (GARDP)2016WHO, Drugs for Neglected Diseases initiativeIdentifies gaps in the antibiotic pipeline and partners with research institutions and pharmaceutical companies to advance product development, particularly of new therapeuticsUS$65 million pledged
Coalition for Epidemic Preparedness Innovations (CEPI)2016Bill & Melinda Gates Foundation,
Wellcome Trust, World Economic Forum, European Commission and the Governments of Australia, Belgium, Canada, Germany, India, Japan, and Norway
Focuses on pre-outbreak vaccine development for priority diseases from the WHO R&D Blueprint for Action to Prevent EpidemicsUS$630 million raised of
US$1 billion goal
  • NTD, neglected tropical disease.